TRML Tourmaline Bio Inc: Forward Price-to-Revenue Multiple
Tourmaline Bio, Inc. (TRML) achieves cost minimization by delegating tests to external CRO networks. This forward P/S metric chart on GURU.Markets demonstrates a balance of expenses, where the indicator reflects current dynamics. Business scalability relies on the global replicability of antibody formulas, while growing authority in immunology confirms the effectiveness of heart inflammation therapy.
Comprehensive metric breakdowns and analytics for Tourmaline (TRML)
- current price and projected stock value:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- business earnings and investment ratios data:
TRML - Net Financial Result|Expected Profit Tourmaline Bio, Inc.|TRML - Price to Earnings Multiple|Forward P/E Multiple Tourmaline Corp|TRML - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Tourmaline|TRML - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Tourmaline Bio|TRML - Earnings per share for the last twelve months|Quarterly EPS earnings growth tourmalinebio.com|TRML - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Tourmaline Bio, Inc.
- revenue and sales details:
Analysis of all company metrics:Tourmaline Bio TRML
The forward P/S reflects the market value of Tourmaline Bio, Inc. (TRML) relative to its expected future sales volume. This indicator measures the premium the market is willing to pay per unit of projected revenue, accounting for discounted growth prospects. Analyzing the forward price-to-sales ratio allows for an assessment of whether the capitalization is appropriate within the context of the development of several antibody programs. The diversification of clinical trials reduces fundamental risks, stabilizing the dynamics of this metric.
Competitors of Tourmaline Bio, Inc.
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|ABVX: Forward Price-to-Revenue Multiple|ADMA Corp - Price to Expected Revenue Ratio|Protagonist Therapeutics (PTGX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio immunovant.com (IMVT)|Forward Price-to-Revenue Multiple KNSA|Forward P/S Multiple Grifols SA|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|CLDX (Celldex Corp) - Forward Price to Sales|Price-to-Projected Revenue Ratio Aurinia Pharmaceuticals AUPH|BCRX - Forward Price-to-Revenue Multiple|Vera Therapeutics - Forward P/S Multiple|DNTH - Forward P/S Multiple|Pharvaris Corp (PHVS) - Price-to-Projected Revenue Ratio|ABCL (AbCellera Corp) - Price-to-Projected Revenue Ratio|PGEN (Precigen, Inc.) - Forward P/S Multiple|pharming.com (PHAR) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Nektar Therapeutics Inc. (NKTR)|Upstream Bio, Inc. - Market Cap to Projected Revenue|Forward P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Immunome Bio (IMNM) - Market Cap to Future Revenue Ratio|GOSS: Forward Price-to-Revenue Multiple|Forward Price to Sales KALV (kalvista.com)|SEPN: Forward P/S Multiple|PVLA (Pieris Pharma) - Price-to-Projected Revenue Ratio|SVRA (Savara Corp) - Forward P/S Multiple|Rigel Corp (RIGL) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio AnaptysBio, Inc. (ANAB)|ATXS - Market Cap to Future Revenue Ratio|enGene - Forward Price-to-Revenue Multiple|Forward Price to Sales RAPT|Aerovate - Forward P/S Multiple|Market Cap to Expected Sales Ratio Aclaris Therapeutics, Inc ACRS|Kyverna Therapeutics (KYTX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TLSA|CABA (Cabaletta Bio) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Ventyx Biosciences Inc. (VTYX)|Forward Price-to-Revenue Multiple THTX (Theratechnologies Inc)|Market Cap to Expected Sales Ratio Avalo Therapeutics Inc|Eledon Pharmaceuticals - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio AGEN (agenusbio.com)|CLYM - Price-to-Projected Revenue Ratio|Forward Price to Sales ZURA (Zura Bio Ltd)|aTyr (ATYR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Adagene Inc.|Price-to-Projected Revenue Ratio ImageneBio|Price-to-Projected Revenue Ratio STTK|Price-to-Projected Revenue Ratio Equillium, Inc. (EQ)|CNTB: Future Price to Revenue|Forward P/S Multiple IMUX (Immunic)|Forward Price to Sales ATRA|InflaRx GmbH - Forward P/S Multiple|XFOR - Forward P/S Multiple|adicetbio.com (ACET) - Price-to-Projected Revenue Ratio|Celularity - Forward Price to Sales|Price-to-Projected Revenue Ratio INmune Bio Corp|Forward Price-to-Revenue Multiple Barinthus Biotherapeutics Corp (BRNS)|Forward P/S Multiple KZR|Forward P/S Multiple sabbiotherapeutics.com (SABS)|Akari Therapeutics Plc - Forward Price-to-Revenue Multiple|Forward Price to Sales ENLV|Q32 Bio Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio GeoVax Corp GOVX|Edesa Biotech, Inc. (EDSA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple ibioinc.com|Price-to-Projected Revenue Ratio Carisma Therapeutics Inc|Forward Price-to-Revenue Multiple XTL Biopharmaceuticals Ltd (XTLB)|Forward Price-to-Revenue Multiple BOLT (Bolt Biotherapeutics)|Forward P/S Multiple hcwbiologics.com (HCWB)|Price-to-Projected Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM: Market Cap to Projected Revenue|Aditxt Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio GRI Bio Inc|XRTX (XORTX) - Forward Price-to-Revenue Multiple|HIND: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Revelation Biosciences|Market Cap to Future Revenue Ratio indaptusrx.com INDP|Forward Price-to-Revenue Multiple SCNI (Scinai Immunotherapeutics Ltd.)|Forward P/S Multiple calcimedica.com (CALI)|Price-to-Projected Revenue Ratio Affimed N.V. AFMD|Forward Price to Sales ALLK|HOOK - Price-to-Projected Revenue Ratio|IGM Biosciences, Inc. (IGMS) - Forward Price-to-Revenue Multiple|ITOS: Forward P/S Multiple|Ocean Biomedical Inc (OCEA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Price-to-Projected Revenue Ratio THRD
